TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31982494

Group type: EXPERIMENTAL
Intervention: Enhanced usual care plus financial incentives
Number of subjects: 182

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 182
Study: 30902701

Group type: EXPERIMENTAL
Intervention: Higher parity (≥5 children)
Number of subjects: 35498

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) <23 kg/m2 with highest parity
Number of subjects: 35498

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) ≥23 kg/m2 with highest parity
Number of subjects: 35498

Group type: EXPERIMENTAL
Intervention: Earlier age at menarche
Number of subjects: 35498

Group type: EXPERIMENTAL
Intervention: Use of oral contraceptives
Number of subjects: 35498

Group type: COMPARATOR
Intervention: Age at menopause
Number of subjects: 35498

Group type: COMPARATOR
Intervention: Use of hormonal therapy
Number of subjects: 35498
Study: 27809724

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser treatment (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Manual subgingival debridement (Group B)
Number of subjects: 30
Study: 25947257

Group type: EXPERIMENTAL
Intervention: Palonosetron (PAL) + Dexamethasone (DEX) on day 1 only
Number of subjects: 82

Group type: COMPARATOR
Intervention: Dexamethasone (DEX) on days 1, 2, and 3
Number of subjects: 82
Study: 23047373

Group type: EXPERIMENTAL
Intervention: Early pregait balance training with visual biofeedback and body weight support harness system
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 28
Study: 22088980

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg daily
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Clopidogrel 225 mg daily
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg daily
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Clopidogrel 225 or 300 mg daily
Number of subjects: 333
Study: 18781341

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (three cycles) of gemcitabine plus carboplatin or paclitaxel
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (three cycles) of gemcitabine plus carboplatin or cisplatin
Number of subjects: 43
Study: 16046076

Group type: EXPERIMENTAL
Intervention: Betablocker (BB) propranolol 80 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 30
Study: 12651798

Group type: EXPERIMENTAL
Intervention: Clinical competence
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patient-centredness
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: More clinically competent interviews
Number of subjects: 60
Study: 10751736

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 100 mg/kg/day for 1-3 weeks
Number of subjects: 118
Study: 8602664

Group type: EXPERIMENTAL
Intervention: 20% magnesium sulfate
Number of subjects: 42

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 42
Study: 1286181

Group type: EXPERIMENTAL
Intervention: Andriol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 2932742

Group type: EXPERIMENTAL
Intervention: Secnidazole (2 g single oral dose)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Tetracycline (750 mg per day for 5 days) plus Clioquinol (1 g per day)
Number of subjects: 80
Study: 30046828

Group type: EXPERIMENTAL
Intervention: CER-001, 3 mg/kg, administered as 10 weekly intravenous infusions
Number of subjects: 293

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293
Study: 26945658

Group type: EXPERIMENTAL
Intervention: Levofloxacin 400 mg (oral)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Levofloxacin 400 mg (oral) + Amikacin 200 mg (intravenous)
Number of subjects: 447
Study: 24751903

Group type: EXPERIMENTAL
Intervention: PEG‐IFNa‐2a
Number of subjects: 30

Group type: COMPARATOR
Intervention: RBV monotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: RBV combination therapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PEG‐IFNa/RBV combination therapy
Number of subjects: 30
Study: 22527075

Group type: EXPERIMENTAL
Intervention: Azithromycin 300 mg/day
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 20075643

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (200-400 mg/d)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 575
Study: 18570573

Group type: EXPERIMENTAL
Intervention: Primary VATS
Number of subjects: 49

Group type: COMPARATOR
Intervention: Chest tube therapy
Number of subjects: 49
Study: 16225405

Group type: EXPERIMENTAL
Intervention: Special care (genetic counseling after explaining the sweat test result and offering of parental DNA testing on the sweat test visit)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard care (sweat test result reported by phone the next day with recommendation for genetic counseling and parental carrier testing)
Number of subjects: 39
Study: 11843062

Group type: EXPERIMENTAL
Intervention: IFN induction/ribavirin
Number of subjects: 256

Group type: COMPARATOR
Intervention: Standard IFN/ribavirin
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: IFN induction/ribavirin (genotype 2b/3a)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Standard combination therapy (genotype 2b/3a)
Number of subjects: 256
Study: 12038914

Group type: EXPERIMENTAL
Intervention: Telephone
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Fax
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: E-mail
Number of subjects: 378

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 378
Study: 9727760

Group type: EXPERIMENTAL
Intervention: Abstracts concluded that the test treatment was as effective as or better than the control treatment
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Abstracts concluded that the test treatment was not as effective as the control treatment
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Sample size of the trials
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Overall publication rates
Number of subjects: 178
Study: 8063650

Group type: EXPERIMENTAL
Intervention: Epinephrine (15 ng.kg‐1.min‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Norepinephrine (30 ng.kg‐1.min‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Epinephrine and Norepinephrine
Number of subjects: 10
Study: 3150128

Group type: EXPERIMENTAL
Intervention: Prolonged physical stress (5 days of continuous heavy exercise, caloric deficiency, and sleep deprivation)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control experiment (performed 8 weeks later)
Number of subjects: 8
Study: 28456058

Group type: EXPERIMENTAL
Intervention: No disclaimer label
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Small disclaimer label
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Large disclaimer label
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Very large disclaimer label
Number of subjects: 320

Group type: COMPARATOR
Intervention: Product images
Number of subjects: 320
Study: 25155105

Group type: COMPARATOR
Intervention: 200 mg on-demand udenafil
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: 50 mg once-daily udenafil
Number of subjects: 161
Study: 23391421

Group type: EXPERIMENTAL
Intervention: G-CSF (10 μg/kg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 21573977

Group type: EXPERIMENTAL
Intervention: Over-the-counter orlistat supply
Number of subjects: 4026
Study: 18500062

Group type: COMPARATOR
Intervention: Mechanical debridement only (Group 1)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Mechanical debridement followed by monopolar radiofrequency (Group 2)
Number of subjects: 29
Study: 17699350

Group type: EXPERIMENTAL
Intervention: Intravenous C.E.R.A. 0.4 microg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Subcutaneous C.E.R.A. 0.8 microg/kg
Number of subjects: 16
Study: 15074443

Group type: EXPERIMENTAL
Intervention: Word recognition in quiet at 60 dB and 80 dB HL
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Word recognition in babble at 4.1 dB S/B
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Word recognition in babble at 9.4 dB S/B
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Word recognition in babble at 6 dB S/B
Number of subjects: 48

Group type: COMPARATOR
Intervention: Listeners with hearing loss
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Test-retest reliability
Number of subjects: 48
Study: 10757572

Group type: EXPERIMENTAL
Intervention: Milrinone (0.5 microg x kg(‐1) x min(‐1))
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (continued catecholamine therapy without milrinone)
Number of subjects: 20
Study: 8817282

Group type: EXPERIMENTAL
Intervention: Valid transient peripheral cue presented 100 ms before target occurrence (100% valid cue with 100 ms lead time)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Noninformative cues presented consistently on either left or right side
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control session with no cue
Number of subjects: 7
Study: 1582303

Group type: EXPERIMENTAL
Intervention: Cefotaxime 2 g every 12 h
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cefotaxime 2 g every 8 h
Number of subjects: 50
Study: 31107983

Group type: EXPERIMENTAL
Intervention: Maternal glycaemic control (higher HbA1c and lower continuous glucose monitoring time‐in‐range)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring time‐in‐target (5-7% increase) during the second and third trimesters
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Neonates with hypoglycaemia
Number of subjects: 225
Study: 28653239

Group type: EXPERIMENTAL
Intervention: Adapted ERAS
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 99
Study: 25952587

Group type: EXPERIMENTAL
Intervention: MSInvigor8-Plus (with email support)
Number of subjects: 39

Group type: COMPARATOR
Intervention: MSInvigor8-Only (without email support)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: MSInvigor8-Plus
Number of subjects: 39

Group type: COMPARATOR
Intervention: MSInvigor8-Only
Number of subjects: 39
Study: 24458836

Group type: EXPERIMENTAL
Intervention: Family-based behavioral weight loss treatment (FBT) program, 16 sessions
Number of subjects: 170
Study: 22078144

Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Face-to-face examination
Number of subjects: 28
Study: 19900797

Group type: EXPERIMENTAL
Intervention: Asthma Control Test (ACT) score
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doctor's assessment of asthma control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient self-assessment of asthma control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Disagreement with doctor's assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Therapeutic interventions (excluding combination products)
Number of subjects: 0
Study: 17667481

Group type: EXPERIMENTAL
Intervention: Intensive behavior therapy
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: MTA children
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Prescribed medication
Number of subjects: 487
Study: 16219252

Group type: EXPERIMENTAL
Intervention: Telephone triage by physicians
Number of subjects: 2560
Study: 12360153

Group type: EXPERIMENTAL
Intervention: Avasimibe at 50 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avasimibe at 250 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avasimibe at 750 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Background lipid-lowering therapy
Number of subjects: 0
Study: 10427802

Group type: EXPERIMENTAL
Intervention: Classical acupuncture (group A)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham acupuncture (group S)
Number of subjects: 14
Study: 7538714

Group type: EXPERIMENTAL
Intervention: TULIP (transurethral ultrasound‐guided laser‐induced prostatectomy)
Number of subjects: 83
Study: 2076239

Group type: EXPERIMENTAL
Intervention: Status composite material
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ful-Fil composite material
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Laminate technique with glass ionomer base
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Unlaminated technique without glass ionomer base
Number of subjects: 40
Study: 6794587

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 20 mg temazepam
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 15 mg flurazepam
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 5 mg nitrazepam
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 10 mg desmethyl‐diazepam
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30573355

Group type: EXPERIMENTAL
Intervention: Drink rich in polyphenols from red grape pomace (RGPD) - 1.562 g gallic acid equivalents (GAE)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control drink (CD, no polyphenols)
Number of subjects: 12
Study: 28059960

Group type: EXPERIMENTAL
Intervention: Primed decision making (video paradigms declared the next operative maneuver)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Unprimed decision making (video paradigms withheld the next operative maneuver)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Decision consistency
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Overall decision making
Number of subjects: 22
Study: 27776459

Group type: EXPERIMENTAL
Intervention: Plant sterols-enriched soy milk (2.0 g free plant sterols daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo soy milk (20g)
Number of subjects: 18
Study: 24061500

Group type: EXPERIMENTAL
Intervention: Hand-assisted colorectal resection
Number of subjects: 245

Group type: COMPARATOR
Intervention: Open colorectal resection
Number of subjects: 245
Study: 22194005

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Endurance Training (ET)
Number of subjects: 15
Study: 19786306

Group type: EXPERIMENTAL
Intervention: Normal saline nasal irrigation
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Normal saline nasal irrigation in atopy group
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no nasal irrigation)
Number of subjects: 69
Study: 17245799

Group type: EXPERIMENTAL
Intervention: Weekly, monthly, or occasional religious participation
Number of subjects: 1610

Group type: EXPERIMENTAL
Intervention: Frequency of religious participation
Number of subjects: 1610

Group type: COMPARATOR
Intervention: No religious participation
Number of subjects: 1610

Group type: COMPARATOR
Intervention: Mental health service utilization
Number of subjects: 1610
Study: 15119158

Group type: EXPERIMENTAL
Intervention: Qi Jie Granule
Number of subjects: 102

Group type: COMPARATOR
Intervention: Qian Jin Pian
Number of subjects: 102
Study: 11309552

Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg once a day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Atenolol (50 mg once a day)
Number of subjects: 12
Study: 9684663

Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 7851254

Group type: EXPERIMENTAL
Intervention: Diabetes education and care program
Number of subjects: 137
Study: 2837300

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg twice each week
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31391505

Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham (placebo) stimulation
Number of subjects: 33
Study: 28147226

Group type: EXPERIMENTAL
Intervention: BLI (blue laser imaging)
Number of subjects: 963

Group type: COMPARATOR
Intervention: WLI (white-light imaging)
Number of subjects: 963
Study: 26345187

Group type: EXPERIMENTAL
Intervention: Yearlong partly supervised mixed exercise intervention (endurance and resistance exercises, 3‐5 times per week)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Progressive muscle relaxation training (Jacobsen method) with the same frequency
Number of subjects: 256
Study: 23997711

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: MAD
Number of subjects: 126
Study: 21228781

Group type: EXPERIMENTAL
Intervention: Multiple guidance group (n = 52)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Single guidance group (n = 57)
Number of subjects: 109
Study: 19549676

Group type: EXPERIMENTAL
Intervention: Anticoagulation protocol during defibrillation testing
Number of subjects: 0
Study: 17717446

Group type: EXPERIMENTAL
Intervention: External stent inserted across the anastomosis to drain the pancreatic duct
Number of subjects: 120

Group type: COMPARATOR
Intervention: No stent
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: External stent inserted
Number of subjects: 120
Study: 16314615

Group type: EXPERIMENTAL
Intervention: ABVD
Number of subjects: 807

Group type: COMPARATOR
Intervention: MDRs
Number of subjects: 807
Study: 12846491

Group type: EXPERIMENTAL
Intervention: Tamoxifen (administered for at least 3 years)
Number of subjects: 0
Study: 9458200

Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Folinic acid
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study: 7544228

Group type: EXPERIMENTAL
Intervention: Procaterol (50 micrograms)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2665661

Group type: EXPERIMENTAL
Intervention: Single dose trimethoprim
Number of subjects: 106

Group type: COMPARATOR
Intervention: Seven day course of co‐trimoxazole
Number of subjects: 106
Study: 81636

Group type: EXPERIMENTAL
Intervention: Inosiplex
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 31780257

Group type: EXPERIMENTAL
Intervention: C-MAC video laryngoscope
Number of subjects: 218

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 218
Study: 31702684

Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NMT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 88
Study: 28231041

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including motivational interviewing by telephone and educational materials with biblical messages, church-based group activities, and environmental cues.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group received the same type and frequency of intervention components related to fruit and vegetable consumption.
Number of subjects: 75
Study: 25782660

Group type: EXPERIMENTAL
Intervention: Infant formula based on whole goats' milk (GIF)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control cows' milk infant formula based on vegetable oils (VIF)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Fully breast-fed infants
Number of subjects: 3
Study: 23280432

Group type: EXPERIMENTAL
Intervention: SIT group (specific immunotherapy)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no SIT)
Number of subjects: 32
Study: 21885491

Group type: EXPERIMENTAL
Intervention: Abatacept plus methotrexate (MTX)
Number of subjects: 0
Study: 19128717

Group type: EXPERIMENTAL
Intervention: Tandem walking at preferred cadence with Swaystar accelerometer
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tandem walking at 75% of preferred cadence with Swaystar accelerometer
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tandem walking at 125% of preferred cadence with Swaystar accelerometer
Number of subjects: 15
Study: 16579323

Group type: EXPERIMENTAL
Intervention: Relapse Prevention Plans (RPPs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 0
Study: 12692541

Group type: EXPERIMENTAL
Intervention: Homozygous recessive for the FUT2 gene (non-expressors of H type-1 oligosaccharide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional FUT2 gene (susceptible population)
Number of subjects: 0
Study: 10582197

Group type: COMPARATOR
Intervention: Nedocromil sodium 4 mg b.i.d. (two times daily)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg q.i.d. (four times daily)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 7788003

Group type: EXPERIMENTAL
Intervention: Propylthiouracil treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (euthyroid patients with simple diffuse goiter)
Number of subjects: 25
Study: 2195937

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (budesonide 200 micrograms twice a day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Inhaled bronchodilators (terbutaline 250 micrograms, two puffs four times a day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Inhaled bronchodilators (Group A)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (Group B)
Number of subjects: 22
Study: 310249

Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mesocaval shunting
Number of subjects: 0
Study: 31719096

Group type: EXPERIMENTAL
Intervention: Group education visits for 12 months
Number of subjects: 212

Group type: COMPARATOR
Intervention: Usual T1D care
Number of subjects: 212
Study: 29118299

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (TAT; aspirin, clopidogrel, and cilostazol)
Number of subjects: 845

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAT; aspirin and clopidogrel)
Number of subjects: 845
Study: 24817596

Group type: EXPERIMENTAL
Intervention: White rice with chicken breast
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: White rice with ground nut oil
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: White rice with leafy vegetable
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: White rice with chicken, oil, and vegetable
Number of subjects: 12

Group type: COMPARATOR
Intervention: White rice alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Glucose solution (reference food)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: White rice with vegetable
Number of subjects: 12
Study: 22569355

Group type: EXPERIMENTAL
Intervention: Piperacillin population pharmacokinetics
Number of subjects: 56
Study: 20144366

Group type: EXPERIMENTAL
Intervention: Diabetes Connected Health (DCH) program - online application for glucose monitoring
Number of subjects: 7
Study: 17803575

Group type: EXPERIMENTAL
Intervention: IPC + CBC
Number of subjects: 40

Group type: COMPARATOR
Intervention: CBC
Number of subjects: 40